Pfizer Inc. (PFE)
| Market Cap | 145.83B |
| Revenue (ttm) | 62.46B |
| Net Income (ttm) | 7.88B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.38 |
| PE Ratio | 18.58 |
| Forward PE | 9.14 |
| Dividend | $1.72 (6.67%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 35,103,066 |
| Open | 25.65 |
| Previous Close | 25.78 |
| Day's Range | 25.42 - 25.72 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 29.92 (+16.65%) |
| Earnings Date | Aug 5, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.92, which is an increase of 16.65% from the latest price.
News
Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys
High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend d...
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently me...
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-run...
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall ...
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus
I present my top 10 high-yield dividend stocks for July 2025, screened for strong yields, large market caps, and attractive valuations. The list includes Chevron, Pfizer, PepsiCo, Ares Capital, BB Seg...
Forget Get Rich Quick: The Real Dividend Strategy That Built My Income Machine
Most people either don't invest, or chase get-rich-quick schemes, which usually leads to disappointment or losses. Setting realistic, achievable financial goals based on savings rate and projected wea...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Pfizer: Options Activity Speaks Bullish
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price....
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED li...
House committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports
The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the company's COVID-19 vaccine...
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass. , June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaki...
Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies
Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents liv...
Pfizer Could Be The Turnaround Story In The Pharmaceutical Space
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...
Pfizer Declares Third-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to...
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding...
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D...
Top stock price forecast: Plug Power, Uber, and Pfizer
The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures...
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
The Dark Side Of Dividend Growth Investing
Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend ...
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...